New CAR-T therapy targets Tough-to-Treat myeloma

NCT ID NCT06185751

Recruiting now Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This early-stage trial is testing a new type of CAR-T cell therapy, called WS-CART-CS1, in 25 people with multiple myeloma that has come back or not responded to at least three prior treatments. The therapy targets a protein called CS1 found on myeloma cells. The main goals are to check safety and see if the treatment can shrink the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CS1 CAR-T cells (WS-CART-CS1)
What this could lead to: If it works, this could offer a new treatment option for multiple myeloma patients who have run out of effective therapies.
What could go wrong: This is an early Phase 1 trial with only 25 participants, so it is too soon to know if it will be safe or effective. CAR-T therapy can cause serious side effects like cytokine release syndrome and neurological problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.